Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2010 2
2011 1
2013 2
2014 2
2015 1
2017 1
2018 1
2019 2
2020 2
2021 3
2022 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
The Role of Eicosanoids in Gynecological Malignancies.
Smith PG, Roque D, Ching MM, Fulton A, Rao G, Reader JC. Smith PG, et al. Among authors: reader jc. Front Pharmacol. 2020 Aug 26;11:1233. doi: 10.3389/fphar.2020.01233. eCollection 2020. Front Pharmacol. 2020. PMID: 32982722 Free PMC article. Review.
Review of Immune Therapies Targeting Ovarian Cancer.
Fan CA, Reader J, Roque DM. Fan CA, et al. Among authors: reader j. Curr Treat Options Oncol. 2018 Nov 14;19(12):74. doi: 10.1007/s11864-018-0584-3. Curr Treat Options Oncol. 2018. PMID: 30430276 Review.
Microtentacle Formation in Ovarian Carcinoma.
Reader JC, Fan C, Ory EC, Ju J, Lee R, Vitolo MI, Smith P, Wu S, Ching MMN, Asiedu EB, Jewell CM, Rao GG, Fulton A, Webb TJ, Yang P, Santin AD, Huang HC, Martin SS, Roque DM. Reader JC, et al. Cancers (Basel). 2022 Feb 4;14(3):800. doi: 10.3390/cancers14030800. Cancers (Basel). 2022. PMID: 35159067 Free PMC article.
Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response.
Rickard BP, Conrad C, Sorrin AJ, Ruhi MK, Reader JC, Huang SA, Franco W, Scarcelli G, Polacheck WJ, Roque DM, Del Carmen MG, Huang HC, Demirci U, Rizvi I. Rickard BP, et al. Among authors: reader jc. Cancers (Basel). 2021 Aug 26;13(17):4318. doi: 10.3390/cancers13174318. Cancers (Basel). 2021. PMID: 34503128 Free PMC article. Review.
Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases.
Duru N, Pawar NR, Martin EW, Buzza MS, Conway GD, Lapidus RG, Liu S, Reader J, Rao GG, Roque DM, Leppla SH, Antalis TM. Duru N, et al. Among authors: reader j. Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2201423119. doi: 10.1073/pnas.2201423119. Epub 2022 Jul 8. Proc Natl Acad Sci U S A. 2022. PMID: 35867758 Free PMC article.
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Roque DM, et al. Among authors: reader jc. Br J Cancer. 2022 Jun;126(12):1695-1703. doi: 10.1038/s41416-022-01717-6. Epub 2022 Feb 11. Br J Cancer. 2022. PMID: 35149854 Free PMC article. Clinical Trial.
22 results